Fluicell AB (5J90) Price & Analysis

3 Followers

5J90 Stock Chart & Stats

€1.29

Market closed

€1.29

Day’s Range― - ―

52-Week Range€0.72 - €5.22

Previous CloseN/A

VolumeN/A

Average Volume (3M)33.00

Market Cap

€3.52M

Enterprise Value€43.46M

Total Cash (Recent Filing)€30.00K

Total Debt (Recent Filing)€2.00M

Price to Earnings (P/E)14.0

Beta5.87

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.04

Shares Outstanding1,373,703

10 Day Avg. Volume100

30 Day Avg. Volume33

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.26

Price to Sales (P/S)2.29

P/FCF Ratio-1.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€6.35M

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Profitability InflectionThe sharp revenue increase alongside a move into positive EBIT and net income indicates improving commercial traction and operating leverage. If sustained, this inflection could strengthen internal funding capacity and support further investment in Fluicell’s single-cell research platforms.

Very High Gross MarginA gross margin near 92% suggests Fluicell’s products and related offerings retain substantial value after direct costs. This creates room to absorb operating expenses, reinvest in product development, and convert future revenue growth into stronger earnings if the margin remains repeatable.

Modest Leverage And Improved Equity BaseLow leverage and a substantial equity base provide financial flexibility compared with a highly debt-funded structure. This balance-sheet position can reduce pressure from financing costs and give Fluicell more capacity to navigate execution setbacks while scaling its biotechnology tools.

Bears Say

Business Is Not Yet Self-fundingNegative operating and free cash flow means reported profitability has not yet translated into internally generated cash. Continued cash burn can require additional financing, restrict investment choices, and leave Fluicell more exposed if commercialization or revenue growth takes longer than expected.

Persistent History Of Losses And Weak Capital ReturnsThe multi-year record of losses, negative cash generation, and negative returns on equity shows that recent improvement has not yet established a durable earnings track record. This history raises execution risk and makes sustained profitability important for validating the business model.

Profitability Durability Remains UnprovenRecent profitability is encouraging, but its durability remains uncertain because Fluicell is a small biotechnology company with a long prior loss history. Any volatility as revenue scales could weaken earnings consistency and delay the point at which growth produces reliable cash generation.

5J90 FAQ

What was Fluicell AB’s price range in the past 12 months?

Fluicell AB lowest stock price was €0.72 and its highest was €5.22 in the past 12 months.

What is Fluicell AB’s market cap?

Fluicell AB’s market cap is €3.52M.

When is Fluicell AB’s upcoming earnings report date?

Fluicell AB’s upcoming earnings report date is Nov 13, 2026 which is in 31 days.

How were Fluicell AB’s earnings last quarter?

Fluicell AB released its earnings results on Aug 28, 2026. The company reported €0.147 earnings per share for the quarter.

Is Fluicell AB overvalued?

According to Wall Street analysts Fluicell AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fluicell AB pay dividends?

Fluicell AB does not currently pay dividends.

What is Fluicell AB’s EPS estimate?

Fluicell AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fluicell AB have?

Fluicell AB has 1,373,703 shares outstanding.

What happened to Fluicell AB’s price movement after its last earnings report?

Fluicell AB reported an EPS of €0.147 in its last earnings report. Following the earnings report the stock price went up 2.572%.

Which hedge fund is a major shareholder of Fluicell AB?

Currently, no hedge funds are holding shares in DE:5J90

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fluicell AB

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.